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The Journal of Immunology
Soluble gC1qR Is an Autocrine Signal That Induces B1R
Expression on Endothelial Cells
Berhane Ghebrehiwet,*,† Yan Ji,* Alisa Valentino,* Lina Pednekar,*,‡
Mahalakshmi Ramadass,† David Habiel,† Richard R. Kew,† Kinga H. Hosszu,*
Dennis K. Galanakis,† Uday Kishore,‡ and Ellinor I. B. Peerschkex,{
Bradykinin (BK) is one of the most potent vasodilator agonists known and belongs to the kinin family of proinflammatory peptides.
BK induces its activity via two G protein–coupled receptors: BK receptor 1 (B1R) and BK receptor 2. Although BK receptor 2 is
constitutively expressed on endothelial cells (ECs), B1R is induced by IL-1b. The C1q receptor, receptor for the globular heads of
C1q (gC1qR), which plays a role in BK generation, is expressed on activated ECs and is also secreted as soluble gC1qR (sgC1qR).
Because sgC1qR can bind to ECs, we hypothesized that it may also serve as an autocrine/paracrine signal for the induction of B1R
expression. In this study, we show that gC1qR binds to ECs via a highly conserved domain consisting of residues 174–180, as
assessed by solid-phase binding assay and deconvolution fluorescence microscopy. Incubation of ECs (24 h, 37˚C) with sgC1qR
resulted in enhancement of B1R expression, whereas incubation with gC1qR lacking aa 174–180 and 154–162 had a diminished
effect. Binding of sgC1qR to ECs was through surface-bound fibrinogen and was inhibited by anti-fibrinogen. In summary, our
data suggest that, at sites of inflammation, sgC1qR can enhance vascular permeability by upregulation of B1R expression through
de novo synthesis, as well as rapid translocation of preformed B1R. The Journal of Immunology, 2014, 192: 377–384.
T
he endothelial cell (EC) receptor for high m.w. kininogen
(HK)—the bradykinin (BK) precursor—consists of recep-
tor for the globular heads of C1q (gC1qR), cytokeratin 1,
and urokinase-type plasminogen activator receptor (uPAR), which
are organized into two bimolecular complexes: uPAR–cytokeratin 1
and gC1qR–cytokeratin 1 (1–7). Within this complex, gC1qR serves
as a strictly zinc-dependent high-affinity site for HK and, there-
fore, is critical for the assembly and activation of the plasma Kinin–
Kallikrein system (KKS), leading to the generation of BK (1, 5).
The KKS consists of three essential proteins that interact in vivo in
a complex fashion once bound to a macromolecular complex formed
during an inflammatory response or bound to proteins along cell
surfaces (8). These are coagulation factor XII (FXII; or Hageman
factor), prekallikrein (PK), and HK. Although FXII preferentially
binds to the uPAR-cytokeratin 1 complex, HK, which circulates
in complex with PK, binds to residues located in its domain 5 (8).
Once FXII is activated to factor XIIa, it converts PK to kallikrein,
a process that is enhanced by heat shock protein 90 and/or the
enzyme carboxypeptidase released by ECs (9). In turn, kallikrein
generated in this manner digests HK to generate the nonapeptide
BK (NH2-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH) (8). BK
belongs to the kinin family of proinflammatory peptides and is
among the most potent vasodilator agonists known (10, 11). Once
generated, it is rapidly converted to des-Arg9-BK by carboxypep-
tidase N, which removes the C-terminal arginine (11). BK induces
its activity via two G protein–coupled receptors: BK receptor 2
(B2R) and BK receptor 1 (B1R). Although B2R is ubiquitously
and constitutively expressed on many healthy cell types, including
ECs, B1R is expressed at low levels, but is induced rapidly, after
tissue damage by IL-1b (12). Furthermore, although BK has a
higher affinity for B2R, des-Arg9-BK is a selective ligand for
B1R. Activation of both receptors, in turn, is known to contribute
to a plethora of acute and chronic pathological disorders, including
hypotension, bronchoconstriction, pain, and inflammation (13, 14).
During the inflammatory response, activated cells, including ECs,
are known to overexpress and to secrete and/or release soluble
gC1qR (sgC1qR). sgC1qR, in turn, binds to intact cells in an
autocrine/paracrine manner (15). Therefore, the present studies
were undertaken to identify the cell surface entity that is the site
for sgC1qR and to assess the possibility that bound sgC1qR is able
to induce B1R expression. The results of these findings are dis-
cussed, and the biological relevance is underscored.
Materials and Methods
Chemicals and reagents
The following reagents and chemicals were used. Dulbecco’s PBS (D-PBS)
with and without calcium and magnesium was obtained from Mediatech
(Manassas, VA). DMEM, RPMI 1640, and 1003 Penicillin/Streptomycin
were obtained from Life Technologies-Invitrogen (Grand Island, NY).
Heat-inactivated FBS was from HyClone (Logan, UT). Human serum al-
bumin was obtained from Immuno U S (Rochester, MI), and Immu-Mount
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was from Thermo Fisher (Waltham, MA). Alexa Fluor 488–streptavidin or
Alexa Fluor 594–streptavidin, Alexa Fluor 488–F(ab9)2 or Alexa Fluor
594–F(ab9)2, goat anti-mouse or anti-rabbit, FITC-conjugated goat anti-
mouse IgG F(ab9)2, and sheep anti-rabbit IgG F(ab9)2 were from Invi-
trogen (Carlsbad, CA). p-nitrophenyl phosphate and alkaline phosphatase–
conjugated rabbit anti-goat IgG were from Pierce (Rockford, IL).
Expression of recombinant gC1qR and its deletion mutants
The strategy for the construction of plasmids containing full-length
gC1qR, as well as deletion mutants lacking highly charged domains
identified from the crystal structure (16), were described in detail in our
earlier publications (17–19).
Cultured cells
Human brain microvascular ECs were cultured in Endothelial Cell Growth
Medium-2 (Lonza, Walkersville, MD) containing 5% heat-inactivated FBS,
as described (20). Cells grown to confluence on 2% gelatin were treated
first (30 min, 37˚C) with 0.25% trypsin, 0.01% EDTA in 0.01 M TBS, to
dissociate cells from the gelatin matrix by incubation. The cells were then
washed and cultured in DMEM. Experiments were done with cells be-
tween passages 3 and 15.
The U937 cell line was grown in suspension in RPMI 1640 containing
10% heat-inactivated FBS, 100 U/ml penicillin, and 100 mg/ml strepto-
mycin (Life Technologies-Invitrogen) and maintained in humidified air
consisting of 5% CO2 and 95% air, as described (21). Prior to each ex-
periment, the viability of cells was verified by Trypan blue exclusion, and
only cultures with $95% viability were used for experiments.
Proteins and Abs
Fibrinogen (FGN) and rabbit anti-FGN IgGwere generated in the laboratory
of Dr. Dennis Galanakis (Stony Brook University). Purified rabbit IgG Abs
to B1R and B2R were purchased from Abcam (Cambridge, MA), and
affinity-purified rabbit IgG (designated pAb UN-15) to a synthetic gC1qR
peptide was made commercially (GenScript, Piscataway, NJ).
SDS-PAGE and Western blot analysis
Analyses by SDS-PAGE were performed on 1.5-mm-thick slab gels, according
to the method of Laemmli (22), with samples being run unreduced or reduced
and alkylated by boiling for 5 min in the presence of 0.1 M DTT and 0.2 M
iodoacetamide. After electrophoresis, the gels were stained either with
Coomassie Brilliant Blue or silver stain, destained, and dried. Samples for
Western blot analysis were run first using SDS-PAGE, as above, electro-
transferred to polyvinylidene difluoride nitrocellulose membranes, and
blocked with 5% nonfat milk containing TBST (20 mM Tris-HCl, 150 mM
NaCl, and 0.05% Tween 20); the bound proteins were probed with a pre-
determined dilution of a specific Ab. The bound Ab, in turn, was visualized
by chemiluminescence HRP-conjugated species-specific Ab, followed by
reaction with 4-chloro-1-naphthol substrate.
Identification of membrane proteins by Ag-capture assay
U937 cells were first grown in RPMI 1640, with or without heat-inactivated
FBS. After the cells reached confluence (∼1 3 106/ml), the contents of each
culture flask (100 ml) were washed separately three times by centrifugation
(8003 g, 4˚C, 10 min). Then, each cell pellet was resuspended in 5 ml 5 mM
D-PBS (pH 7.5) containing 0.5 mM EDTA, 10 mM EACA, and 0.5 mM
PMSF. Cell membranes were prepared by freeze-thawing in liquid nitrogen,
followed by centrifugation (1 h, 45,0003 g, 4˚C). The supernatant containing
the cytosolic fraction was removed, and the pellet containing the cell mem-
brane was used to prepare membrane proteins by solubilization in D-PBS
containing 1% Nonidet P-40. The solubilized membrane proteins were freed
from insoluble material by centrifugation (1 h, 30,000 3 g, 4˚C), after which
the total protein concentration was determined using the detergent-compatible
BCA Protein Assay kit (Pierce). The membrane proteins were kept frozen at
280˚C in small aliquots until use.
To identify the membrane protein recognized by sgC1qR, 10 microtiter
wells were coated with 100 ml 100 mg/ml gC1qR peptide 174–180 or 100
ml 5 mg/ml gC1qR. The wells were incubated (37˚C, 2 h), after which the
unbound proteins were discarded, and the unreacted sites of the well were
blocked with 3% BSA (room temp, 1 h). Next, the wells were washed
three times with Tris-buffered solution containing 0.1 Triton X-100, and
100 ml membrane proteins was added to each well and incubated over-
night at 4˚C. After removal of the unbound proteins, the wells were
washed three times with Tris-buffered solution containing 0.1 Triton
X-100, 100 ml glycine was added to each well, and the samples were left
on a shaker for 1 h at room temperature. The glycine from each well was
pooled to give a total volume of 1 ml for each protein sample, and this
was added to 4 ml cold acetone. The mixture was left at 220˚C for 1 h to
allow precipitation of the proteins. Then, the samples were spun at
13,000 rpm (Eppendorf centrifuge) for 10 min, SDS sample buffer was
added to the pellet, and the sample was analyzed by SDS-PAGE and
silver staining.
To ensure that the membrane protein identified was indeed membrane
associated, the above protocol was repeated using surface biotinylated U937
cells and processed as above.
Flow cytometry
U937 cells were collected and washed in PBS containing 1% BSA and
0.01% NaN3 (PBS-A). Nonspecific binding was blocked with 1 mg/ml
human IgG or Fc fragments in PBS-A/1 3 106 cells (30 min, 4˚C), and
primary Abs or the appropriate isotype-matched controls were added to the
cells (30 min, 4˚C). Cells were washed twice in PBS-A and incubated with
FITC-labeled secondary Abs (30 min, 4˚C). The cells were washed with
PBS-A, fixed in 10% formalin, and analyzed by flow cytometry using a
FACSCalibur (Becton-Dickinson, Mountain View, CA). For each analysis,
5000 events were collected. The data were analyzed using CellQuest Pro
software (Becton-Dickinson).
Immunofluorescence microscopy
Immunofluorescence studies were performed on either U937 cells or
human brain microvascular endothelial cells. The cells were grown on
glass cover slips, and the attached monolayer of cells was incubated with
PBS containing 0.1% BSA and 1% heat-inactivated human serum or
1 mg/ml Fc fragments to block FcRs, followed by incubation with bio-
tinylated gC1qR and FITC-conjugated secondary reagents, as described
above. After fixing for 10 min with 10% (v/v) formalin, the cover slips
were air-dried, placed face down onto microscope slides, sealed using
mounting solution (Immu-Mount), and examined by three-dimensional
imaging using deconvolution microscopy. Staining with anti–von Willebrand
factor (vWF) was always included to ensure the authenticity of the EC
phenotype.
Solid-phase binding to microplate-fixed U937 cells
The ability of gC1qR and its deletion mutants to bind to U937 cells was tested
using a microtiter plate assay with fixed cells, as described elsewhere (23, 24).
Briefly, intact U937 cells (23 105 cells /well) were attached (30 min, 22˚C)
to poly-L-lysine–coated (10 mg/ml in PBS [pH 7.4]) duplicate ELISAwells.
Subsequently, the cells were fixed (30 min, 22˚C) by addition of an equal
volume of glutaraldehyde (0.5% solution in PBS), and the unreacted sites
were quenched with glycine-BSA (100 mM glycine, 0.1% BSA in PBS [pH
7.4]). Next, biotinylated gC1qR or deletion mutants ranging from 0 to 5 mg/
ml were added and incubated (60 min, 22˚C), and the bound gC1qR proteins
were detected by sequential interaction with alkaline phosphatase–conju-
gated Neutravidin, followed by p-nitrophenyl phosphate substrate.
Effect of gC1qR on B1R and B2R expression
To test the effect of gC1qR on the expression of B1R or B2R, ECs were
grown overnight in fibronectin-coated six-well plates in 1 ml Endothelial
Cell Growth Medium-2 to ensure that cell attachment was complete. After
blocking FcRs, as described above, concentrations of wild-type gC1qR or
gC1qR deletion mutants were added and incubated for either 2 or 24 h.
After incubation, the supernatant from each well was removed, and the
cells were washed in fresh medium and incubated with 5 mg/ml anti-B1R
or anti-B2R Ab (1 h, room temp). After removing the unbound Ab, the cells
were washed and incubated (1 h, room temp) with FITC-conjugated goat
anti-rabbit IgG fixed with 10% formalin and analyzed by deconvolution
microscopy.
Statistical analysis
Student t tests were performed using statistical software (Excel; Microsoft,
Redmond, WA). A p value = 0.05 was considered significant (n represents
separate experiments performed in duplicates).
Results
The full-length gC1qR (residues 1–282) is located on the cell
surface
Previous studies from our laboratory (18) showed that the “mature
form” of gC1qR (residues 74–282) was present on the cell surface.
However, the presence of the full-length gC1qR (residues 1–282)
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was not studied on the premise that the full length was synthesized
as a “pre-pro” protein in the mitochondria and then cleaved to
generate the membrane-associated “mature” protein. To determine
whether the full-length gC1qR was localized on the membrane,
immunofluorescence studies were performed using monospecific
polyclonal IgG (pAb UN15) recognizing a synthetic peptide within
the N-terminal residues 1–74. As shown in Fig. 1, this Ab was able
to stain the EC surface, and this staining colocalized with that of
mAb 74.5.2, which recognizes the HK site located within residues
204–218 of gC1qR (1).
Incubation of gC1qR with ECs induces the expression of B1R
Activated cells or cells undergoing proliferation are known to
secrete a soluble form of gC1qR, which is structurally and func-
tionally similar to gC1qR purified from cell membranes (15).
However the role of sgC1qR is not completely understood. We
FIGURE 1. Colocalization of the mature
and full-length gC1qR on the cell surface of
ECs. Human brain microvascular cells were
grown on glass cover slips, and the attached
monolayer of cells were incubated with PBS
containing 0.1% BSA and 1 mg/ml Fc frag-
ments to block FcRs, followed by incubation
with MOPC-21 (A), mAb 74.5.2, or pAb
UN15. The bound Abs were probed with ei-
ther Alexa Fluor 488–F(ab9)2 anti-mouse Abs
(B) or Alexa Fluor 594–F(ab9)2 anti-rabbit
Abs (C). (D) The merged picture shows
staining with mAb 74.5.2 and pAb UN15.
Original magnification 368. The experiment
is a representative of three such experiments.
The control staining with rabbit nonimmune
IgG, was similar to that in (A) and is not
included.
FIGURE 2. sgC1qR binds to ECs. (A) Cells were stained with biotinylated gC1qR (ranging from 0 to 5 mg/ml), and the fluorescence intensity of each
staining (n = 2) was plotted to show dose dependence. (B) The comparative immunofluorescence staining between biotinylated gC1qR (5 mg/ml) and
biotinylated gC1qR deletion mutant lacking residues 174–180 (D174–180). Original magnification 368. The negative control was ECs incubated with
5 mg/ml unbiotinylated gC1qR.
The Journal of Immunology 379
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showed previously that sgC1qR, purified from culture super-
natants of U937 cells, can bind to intact U937 cells, and this
binding was similar to that obtained with recombinant gC1qR
(15). In the present studies, we used immunofluorescence staining
and deconvolution microscopy to show that recombinant and bio-
tinylated gC1qR can also bind to ECs (Fig. 2) in a manner that is
dose dependent (Fig. 2A). To assess the biologic consequence of
this binding, we performed preliminary studies to determine the
optimal concentration for saturation, which was in the range of
2.5–5 mg/ml (Fig. 2A). Then, experiments were performed to
determine what effect such binding has on B2R and/or B1R ex-
pression. The results confirm that, although B2R is constitutively
expressed, and ECs cultured alone stain very strongly with anti-
B2R, there was, nonetheless, a modest and quantifiable increase
(∼1.5–2-fold) in B2R surface expression when the ECs were
cultured for 24 h in the presence of gC1qR (Fig. 3). In contrast,
although ECs usually have small, but detectable, amounts of B1R
on their surface, the staining with anti-B1R increases drastically
(5–10-fold, deduced from measurement of fluorescence intensity)
in the presence of increasing concentrations of gC1qR, reaching
maximal staining with 5 mg/ml gC1qR (Fig. 3).
Domain 174–180 is the primary attachment site for sgC1qR
The above experiments, together with data from previous studies,
conclusively showed that sgC1qR is able to bind to various cell
types, including U937 cells (15) and ECs, as shown in this study.
FIGURE 3. sgC1qR induces the expres-
sion of B1R. ECs were grown for 24 h, as
described Fig. 1, until full attachment and
cobblestone formation were achieved. The
cells were then cultured or not with 5 mg/ml
gC1qR for an additional 24 h. The expres-
sion of B2R or B1R was examined by in-
cubation of the cells with the corresponding
Abs and analyzed by deconvolution immu-
nofluorescence microscopy. Original mag-
nification 368.
FIGURE 4. Comparison of the effect of WT gC1qR and its deletion mutants on B1R expression. The binding of biotinylated (2 mg/ml) gC1qR and
various deletion mutants (D) to ECs was assessed by immunofluorescence microscopy (upper panels). Original magnification 368. The mean intensity of
each staining is plotted (lower panel) for comparison. The experiment is a representative of three experiments run in triplicates.
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However, neither the domain of gC1qR that allows for such
binding nor the cellular entity that is the putative site for gC1qR is
known. In an effort to identify the gC1qR cell-binding domain, we
compared the binding of wild-type gC1qR with 10 types of gC1qR
deletion (D) mutants lacking highly charged surface-exposed domains.
As shown in Fig. 4, gC1qR lacking residues 174–180 or 144–162,
154–162, and 196–202 consistently showed diminished binding to
ECs, suggesting that at least two sites exist: one at 174–180 and
another in an overlapping site between 144–162 and 154–162. Be-
cause subsequent binding studies using microtiter plate–fixed U937
cells showed diminished binding with gC1qRD174–180, we gener-
ated two synthetic peptides: one corresponding to residues 174–180
and another to 144–162. These peptides were then used in an Ag-
capture ELISA to pull down solubilized membrane protein(s) from
surface biotinylated U937 cells. As shown in Fig. 5A, only peptide
174–180 was able to pull down biotinylated membrane protein(s). To
visualize and examine the structure of the captured protein, pull-down
experiments were performed using intact gC1qR and peptide 174–
180. When the captured U937 membrane proteins were analyzed by
SDS-PAGE and silver staining under denaturing and reducing con-
ditions (Fig. 5B), a predominant molecule with a chain structure and
total m.w. that resembled FGN was visualized. In addition, two low
m.w. bands, which have structural similarity to C1q, were captured by
peptide 174–180. Therefore, subsequent pull-down experiments were
designed to verify that the gC1qR-bound U937 membrane proteins
were indeed FGN. As shown in Fig. 5C, the protein bands captured
by gC1qR reacted strongly with anti-FGN. The specificity of this
interaction is supported by the fact that neither the captured bands nor
highly purified FGN used as control reacted with isotype- and
species-matched IgG (Fig. 5C).
Cell surface–expressed FGN is the binding site for sgC1qR
To our knowledge, the presence of FGN on cell surfaces has not
been reported before. Therefore, based on the experiments depicted
in Fig. 5, we proceeded to look for the presence of FGN on the cell
surface. The initial strategy was to use highly specific anti-FGN
IgG to detect the presence of FGN on microtiter plate–fixed U937
cells grown either in complete medium containing FBS or serum-free
growth medium. This preliminary experiment showed a strong anti-
FGN binding compared with isotype- and species-matched IgG.
Subsequent experiments were designed to determine whether anti-
FGN Abs could inhibit gC1qR binding to microtiter plate–fixed
U937 cells. As shown in Fig. 6, a statistically significant inhibition
(p = 0.032) was observed when cells were treated with anti-FGN
IgG prior to incubation with gC1qR. Immunofluorescence staining
experiments further confirmed the presence of FGN on U937 cells
(Fig. 7) and ECs (Fig. 8). In addition, it was interesting to note that, at
least on U937 cells, the expression of both FGN and gC1qR was
“patchy” and both colocalized in these patchy sections of the cell
membrane (Fig. 7). Furthermore, not all cells stained positive, and
cells that appeared to undergo cell division stained more robustly,
which may indicate that FGN is expressed at specific stages of cell
division and proliferation. Controls were always included to verify
that the ECs that were positive for FGN were also positive for
vWF (Fig. 9).
FIGURE 5. Intact gC1qR and gC1qR peptide 174–180 recognize the same membrane protein. (A) ELISA-based Ag capture assay in which duplicate
wells of a microtiter plate were coated with 100 ml (100 mg/ml) of either gC1qR peptide 174–180 or peptide 144–162. After blocking with 1% BSA, the
wells were incubated (overnight, 4˚C) with 100 ml of surface biotinylated U937 membrane proteins, and the captured protein(s) were detected with alkaline
phosphatase–conjugated Neutravidin and developed following standard ELISA procedures. (B) Pull-down experiment in which membrane proteins were
captured by either peptide 174–180 (lane 1) or intact gC1qR (lane 2). The captured proteins were eluted with glycine, acetone precipitated, and, after
addition of SDS sample buffer, analyzed by SDS-PAGE under reducing conditions. Protein bands were visualized by silver staining. (C) The three bands
between 75 and 50 kDa in lanes 1 and 2 in (B) are the a, b, and g-chains of FGN and are recognized by anti-FGN IgG and not by nonimmune IgG (NIRG).
FIGURE 6. Anti-FGN IgG inhibits gC1qR binding to U937 cells. The
binding of biotinylated gC1qR to microtiter plate–fixed U937 cells was
assessed by standard ELISA in the presence or absence of anti-FGN IgG or
nonimmune rabbit IgG as control.
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Discussion
Earlier molecular-cloning studies suggested that gC1qR is syn-
thesized as a pre-pro or “full-length” protein of 282 residues,
which is then cleaved at position 73–74 to generate the “mature
form” (residues 74–282) found on the cell membrane (18). How-
ever, when a monospecific polyclonal Ab recognizing a peptide
(residues 50–63) in the N terminus of gC1qR was used in im-
munofluorescence studies, a robust membrane staining was ob-
served (Fig. 1), indicating the presence of either the full-length
protein or a fragment that contains residues 1–73. This staining
was not only comparable to the staining observed with mAb
74.5.2, which recognizes residues 204–218, but more importantly,
the molecule(s) recognized by both Abs were colocalized on the
membrane, indicating that these Abs recognize the same mole-
cule. Therefore, this experiment clearly shows that, in addition to
its localization inside the cell, the full-length molecule is present
on the cell membrane, probably in the lipid rafts bound to cho-
lesterol (25) via a cholesterol recognition amino acid consensus
motif, which is present on gC1qR. This, in turn, suggests that the
membrane-bound mature protein (residues 74–282) may be gener-
ated from the full-length protein during cell activation or stimulation.
Most proliferating cells, such as cancer, inflammatory, or acti-
vated cells, are known to overexpress, as well as secrete, gC1qR
into the pericellular milieu, where it can potentially modulate a
diverse range of physiological and immunological functions, in-
cluding angiogenesis (26), vascular permeability (9, 27), and in-
flammation (27), through activation of the complement system and
KKS. This is due, in part, to the susceptibility of gC1qR to pro-
teolytic cleavage by enzymes in plasma or membrane-associated
enzymes, such as MT1-MMP, as shown earlier (28). Because pre-
vious studies (12) showed that sgC1qR (either recombinant or pu-
rified from cell cultures) can bind to U937 cells, the present studies
were designed to examine the function of sgC1qR by addressing
three interrelated questions. Does gC1qR bind to ECs? And if so,
FIGURE 7. FGN and gC1qR are colo-
calized on the surface of U937 cells. U937
cells that were grown to confluence in se-
rum-free medium were incubated with 5 mg/
ml rabbit nonimmune IgG (RbIgG) or MOPC-
21 (MsIgG) or with rabbit anti-FGN or
mAb74.5.2 anti-gC1qR. The bound Ab was
visualized using Alexa Fluor 488–conjugated
(green) or Alexa Fluor 594–conjugated (red)
F(ab9)2 secondary Ab. Original magnifica-
tion368. After fixing, the cells were analyzed
by immunofluorescence staining and decon-
volution microscopy.
FIGURE 8. Colocalization of gC1qR and
FGN on the EC surface. (A) ECs were grown
on cover slips and incubated with anti-FGN,
biotinylated-gC1qR (Biot.gC1qR), or both
(merge). Cells incubated without primary
Ab (No 1eAb) were used as negative control.
(B) Cells showing colocalization of FGN
and gC1qR (merge) were subjected to three-
dimensional rotation to show staining of
cells as seen from the front (or top), the
side (90˚ rotation), or back (360˚ rotation).
Original magnification 368.
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what surface molecule(s) serves as the gC1qR site? And does the
binding of gC1qR serve to stimulate or suppress B1R, which,
unlike B2R, is induced at inflammatory sites by IL-1b and/or
other factors (13, 14, 29, 30). The rationale for using both ECs
and U937 cells is two-fold. First, both are gC1qR-expressing
proinflammatory cells in which the effect of the gC1qR-mediated
response could be easily monitored. Second, we can grow U937 cells
in large numbers for flow cytometry, as well as for fixation to
microtiter plates for ELISA-type experiments.
The data obtained in the present studies show that gC1qR is
able to bind to ECs in a dose-dependent manner (Fig. 2), as well
to enhance the expression of B2R and, more importantly, induce
the expression of B1R (Fig. 3). To identify the region or domain
of gC1qR responsible for this binding, experiments were per-
formed in which the binding of wild-type gC1qR to U937 cells
or ECs was compared with the binding of several gC1qR dele-
tion mutants, each lacking a highly charged domain exposed
on the surface of the molecule (16, 17). The results of these
experiments showed that the binding of gC1qR deletion mutants
lacking residues 174–180, 144–162, and 154–162 were signifi-
cantly reduced compared with wild-type gC1qR (Fig. 4). How-
ever, subsequent experiments showed that only peptide 174–180,
and not peptide 144–162, was able to recognize a membrane
protein from U937 cells. These results suggest that the primary
or initial gC1qR interaction site may be through domain 174–
180, with subsequent multisite and stable binding occurring
through other sites, including a site found within residues 144–
162. In support of this hypothesis is the finding that, although
both gC1qR and peptide 174–180 captured a membrane protein
from U937 cells, peptide 144–162 did not. The captured protein(s),
in turn, appears to be surface-bound FGN, because pull-down
experiments followed by silver staining (Fig. 5) analysis showed a
three-chain molecule whose chain structure and m.w. appeared to be
remarkably similar to FGN; anti-FGN Abs inhibited binding of
gC1qR to U937 cells; and both U937 cells (Fig. 7) and ECs (Fig.
8) stained strongly for FGN and less strongly for vWF (Fig. 9) when
analyzed by immunofluorescence staining. In earlier unrelated stud-
ies, it was shown that recombinant gC1qR bound to human FGN and
impaired its polymerization (31). The binding site for gC1qR was
found to be on the D domain of FGN/fibrin, with the carboxyl-
terminal segment of at least the FGN/fibrin g-chain being im-
portant for this interaction. These observations suggested a potential
role for gC1qR in modulating fibrin formation, particularly at local
sites of immune injury or inflammation (31). Therefore, although
the observation of gC1qR/FGN interaction is not surprising, the fact
that this interaction occurs at the cell surface is, and it represents
a novel biological function for sgC1qR.
The results described in this article are significant at many levels.
First, as we showed previously (32), sgC1qR can bind ECs. Al-
though recombinant gC1qR, which is not glycosylated, was used in
these studies, the soluble form of gC1qR that is naturally secreted
by activated cells, including ECs, is glycosylated, and this form
is likely to be even more effective than the gC1qR used in these
studies. Highly activated cells, especially tumor cells or cells at
inflammatory sites, overexpress gC1qR on their surface and release
a soluble form of the molecule into the pericellular milieu. Each
form of the gC1qR molecule—surface expressed or soluble—was
shown to play a role in the induction and/or perpetuation of the
inflammatory process by activation of KKS, as well as by activation
of the classical pathway of the complement system (15). Second,
activation of KKS leads to the generation of BK (amino acid se-
quence Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), which acts on B2R
to initiate vascular permeability. In humans, the half-life of BK is
extremely short because it is degraded rapidly by three kininases:
angiotensin-converting enzyme, aminopeptidase P, and the car-
boxypeptidases N or M (membrane-bound enzyme), which cleave
the 7–8, 1–2, and 8–9 positions, respectively (33, 34). Of these, the
first degradation product of BK—des-Arg9-BK—is more stable and
possesses high affinity for B1R. Although a detectable amount of
B1R exists on the cell surface, B1R is induced by IL-1b produced
by monocytes recruited to the inflammatory site. Third, sgC1qR
is capable of inducing B1R expression and, thus, enhancing BK-
mediated vascular permeability, and it is also able to recruit C1q,
a powerful chemoattractant (35, 36), which like activated HK, is
able to generate proinflammatory cytokines, such as TNF-a, IL-1b,
and IL-6, and the chemokines IL-8 and MCP-1 (37, 38). Thus, at
sites of inflammation or diseases states, such as angioedema, in
which vascular permeability plays a central role, gC1qR can serve
as an important catalyst by orchestrating various proinflammatory
cascades. Therefore, it represents a suitable target for the generation
of peptide-based or Ab-based therapy to prevent local or systemic
inflammation.
FIGURE 9. Comparison of the expression of FGN and vWF on EC surface. Cells were grown on cover slips and incubated with 5 mg/ml anti-FGN (C),
anti-vWF (B), or species-matched IgG (A). The bound Ab was visualized using Alexa Fluor 488–F(ab9)2 secondary Ab, as described in Materials and
Methods. Original magnification 368.
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